Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03038594
Other study ID # 19-0298 / 15-0192
Secondary ID W81XWH-15-1-0143
Status Completed
Phase Phase 2/Phase 3
First received
Last updated
Start date November 1, 2015
Est. completion date November 30, 2021

Study information

Verified date February 2023
Source The University of Texas Medical Branch, Galveston
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The investigators have previously demonstrated that burn injury causes severe muscle wasting, weight and height retardation, and systemic protein catabolism in pediatric and adult burned patients. The persistent loss of muscle impairs the quality of life of the burned patients, and it also delays autonomy and reintegration into the community. In 2009, the investigators showed that the daily injection of recombinant human growth hormone (GH) for nine months post discharge significantly increased height and weight, as well as lean body mass, in pediatric burned subjects. Our long-term goal is to improve the quality of life of burn patients by preventing height, weight, and muscle loss that may occur from severe protein catabolism. The objectives of this application are to a) attenuate height and weight in burned patients with the administration of GH, b) prevent or reverse loss of muscle and strength in these patients, and c) collect pilot data about cardiopulmonary parameters, scar assessments, and muscle metabolism. Our central hypothesis is that the administration of GH will restore depleted levels of growth hormone and will lead to prevention of lean body mass loss and bone mineral content, improve rehabilitation, and accelerate reintegration of severely burned patients. The investigators will administer either placebo or GH (daily subcutaneous injections of 0.05 mg/kg/day of GH [somatropin, Genotropin, Pfizer, New York, NY] to adult burn subjects (n=31 per group, 18-85 years, >30% total body surface burns) for nine months beginning one week prior to discharge. Both groups will be studied for a total of two years. The following aims will be tested: 1) determine the effects of GH supplementation on body composition, such as lean body mass loss, muscle strength, and exercise endurance; and 2) assess whether rehabilitation and subsequent reintegration of severely burned patients into society can be accelerated. Investigators will measure changes in lean body mass, muscle strength and exercise endurance during the acute hospital stay, discharge, and long-term follow-up visits (6, 12, 18, and 24 months after burn), as well as secondary endpoints such as cardiopulmonary variables, hypertrophic scar development, quality of life questionnaires, and concentrations of relevant hormones, cytokines, and oxidative stress markers.


Description:

Either recombinant human growth hormone (daily subcutaneous injections of 0.05 mg/kg/day of GH at discharge [somatropin, Genotropin, Pfizer, New York, NY]; 0.025 mg/kg/day of GH titrated the week before discharge) or placebo (n=31) will be administered to adult burned subjects (n= 31, 18-85 years) after screening and voluntary consent who have ≥30% TBSA assessed by either the Lund and Browder chart or the 'rule of nines' method during excisional surgery. It will be administered daily for 9 months beginning the week before discharge, and the primary and secondary endpoints will be collected during the acute hospital stay, discharge, and long-term follow-up visits (6, 12, 18, and 24 months after burn injury). Additionally, subjects will be contacted frequently [most likely 1 week, 1 month, and 2 months post discharge by telephone] to ensure that there are no adverse events or concerns with their study drug, as well as visit with them during their clinical visits that address their post-burn needs. All subjects will receive similar standard medical care and treatment from the time of emergency admission until their discharge. Growth hormone will be used to potentially attenuate losses in height, weight, muscle and bone, reverse the oxidative stress of burn injury and, in the process, decrease the secondary consequences of burn injury, including organ dysfunction. This may improve the quality of life of the burn patient by preventing pathophysiology that may result from muscle and bone loss and may reduce hospital stay. Our research will lay the foundation for the future development of effective, safe, and economic therapeutic interventions to treat burn injury-associated metabolic abnormalities. Also, it will provide the basis for the development of supplemental regulations and pharmacotherapy to treat burn patients with GH. The risks are very reasonable in relation to the anticipated benefits to our subjects because a) GH at a higher dose has been tested in pediatric burned subjects with minor adverse events, and b) the subjects will be monitored consistently.


Recruitment information / eligibility

Status Completed
Enrollment 13
Est. completion date November 30, 2021
Est. primary completion date November 2, 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years to 85 Years
Eligibility INCLUSION CRITERIA - 18-85 years old - Over 30% total body surface area burn - Provide consent and comprehend English or Spanish EXCLUSION CRITERIA - History of AIDS, AIDS-related complex, or HIV - History of or current hepatitis B or C - Pregnancy - History of or Active Malignancy - Insulin dependent diabetes mellitus type I prior to admission - Insulin dependent diabetes mellitus type II (up to 12 months prior to admission) - Other hyperglycemic disorders [not including transient post-burn/trauma hyperglycemia] - Current oral corticosteroid treatment - Currently participating in another interventional clinical trial at UTMB

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Somatropin

0.09% Saline Solution


Locations

Country Name City State
United States University of Texas Medical Branch Galveston Texas

Sponsors (3)

Lead Sponsor Collaborator
The University of Texas Medical Branch, Galveston Pfizer, United States Department of Defense

Country where clinical trial is conducted

United States, 

References & Publications (1)

Stylianos S, Eichelberger MR. Pediatric trauma. Prevention strategies. Pediatr Clin North Am. 1993 Dec;40(6):1359-68. doi: 10.1016/s0031-3955(16)38666-7. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Lean body mass Dual-Energy X-ray Absorptiometry (DEXA) measured in grams At baseline
Primary Lean body mass Dual-Energy X-ray Absorptiometry (DEXA) measured in grams 6 months post burn-injury
Primary Lean body mass Dual-Energy X-ray Absorptiometry (DEXA) measured in grams 12 months post burn-injury
Primary Lean body mass Dual-Energy X-ray Absorptiometry (DEXA) measured in grams 18 months post burn-injury
Primary Lean body mass Dual-Energy X-ray Absorptiometry (DEXA) measured in grams 24 months post burn-injury
Secondary Change in Muscle strength (peak torque) resistance testing muscle strength (assessed by Biodex isokinetic dynamometer) Discharge (usually 30 days post burn) and 6, 12, 18, and 24 months after burn injury
Secondary Change in Muscle strength ( total work) resistance testing muscle strength (Biodex isokinetic dynamometer) Discharge (usually 30 days post burn) and 6, 12, 18, and 24 months after burn injury
Secondary Change in Muscle strength (average power) resistance testing muscle strength (assessed by Biodex isokinetic dynamometer) Discharge (usually 30 days post burn) and 6, 12, 18, and 24 months after burn injury
Secondary Change in Muscle grip strength (maximum power) testing muscle strength (assessed by hand dynamometer) Discharge (usually 30 days post burn) and 6, 12, 18, and 24 months after burn injury
Secondary Change in Muscle endurance (maximum power) testing muscle endurance (assessed by Bruce treadmill test) Discharge (usually 30 days post burn) and 6, 12, 18, and 24 months after burn injury
Secondary Change in Resting energy expenditure (REE) Indirect calorimetry Discharge (usually 30 days post burn) and 6, 12, 18, and 24 months after burn injury
Secondary Change in resting heart rate electrocardiogram (EKG) readings Discharge (usually 30 days post burn) and 6, 12, 18, and 24 months after burn injury
Secondary Change in liver size Ultrasound readings Discharge (usually 30 days post burn) and 6, 12, 18, and 24 months after burn injury
Secondary Change in cardiac stroke volume echocardiogram readings Discharge (usually 30 days post burn) and 6, 12, 18, and 24 months after burn injury
Secondary Change in cardiac output Echocardiogram readings Discharge (usually 30 days post burn) and 6, 12, 18, and 24 months after burn injury
Secondary Change in respiratory quotient Indirect calorimetry Discharge (usually 30 days post burn) and 6, 12, 18, and 24 months after burn injury
Secondary Change in Total body fat Dual-Energy X-ray Absorptiometry (DEXA) Discharge (usually 30 days post burn) and 6, 12, 18, and 24 months after burn injury
Secondary Change in percentage of total body fat Dual-Energy X-ray Absorptiometry (DEXA) Discharge (usually 30 days post burn) and 6, 12, 18, and 24 months after burn injury
Secondary Change in bone mineral content Dual-Energy X-ray Absorptiometry (DEXA) Discharge (usually 30 days post burn) and 6, 12, 18, and 24 months after burn injury
Secondary Change in bone mineral density Dual-Energy X-ray Absorptiometry (DEXA) Discharge (usually 30 days post burn) and 6, 12, 18, and 24 months after burn injury
Secondary Change in Maximal oxygen consumption Six-minute walk test Discharge (usually 30 days post burn) and 6, 12, 18, and 24 months after burn injury
Secondary Change in respiratory fatigue Six-minute walk test Discharge (usually 30 days post burn) and 6, 12, 18, and 24 months after burn injury
Secondary Change in leg fatigue Six-minute walk test Discharge (usually 30 days post burn) and 6, 12, 18, and 24 months after burn injury
Secondary Change in Muscle protein synthesis rate Deuterium water Discharge (usually 30 days post burn) and 6, 12, 18, and 24 months after burn injury
Secondary Hypertrophic scar development Vancouver Scar Scale Discharge (usually 30 days post burn) and 6, 12, 18, and 24 months after burn injury
Secondary Change in Forced vital capacity (FVC) Pulmonary function test Discharge (usually 30 days post burn) and 6, 12, 18, and 24 months after burn injury
Secondary Change in forced expiratory volume in one second (FEV1) Pulmonary function test Discharge (usually 30 days post burn) and 6, 12, 18, and 24 months after burn injury
Secondary Change in forced expiratory flow rate between 27-75% of the FVC (FEF25-75) Pulmonary function test Discharge (usually 30 days post burn) and 6, 12, 18, and 24 months after burn injury
Secondary Change in FEV1/FVC ratio expressed as a percentage (FEV1/FVC%) Pulmonary function test Discharge (usually 30 days post burn) and 6, 12, 18, and 24 months after burn injury
Secondary Change in vital capacity (VC) Pulmonary function test Discharge (usually 30 days post burn) and 6, 12, 18, and 24 months after burn injury
Secondary Change in total lung capacity (TLC) Pulmonary function test Discharge (usually 30 days post burn) and 6, 12, 18, and 24 months after burn injury
Secondary Change in residual volume (RV) Pulmonary function test Discharge (usually 30 days post burn) and 6, 12, 18, and 24 months after burn injury
Secondary Change in functional residual capacity (FRC) Pulmonary function test Discharge (usually 30 days post burn) and 6, 12, 18, and 24 months after burn injury
Secondary Change in lung diffusion capacity (DLCO) Pulmonary function test Discharge (usually 30 days post burn) and 6, 12, 18, and 24 months after burn injury
Secondary Change in maximum voluntary ventilation (MVV) Pulmonary function test Discharge (usually 30 days post burn) and 6, 12, 18, and 24 months after burn injury
Secondary Change in peak expiratory flow (PEF) Pulmonary function test Discharge (usually 30 days post burn) and 6, 12, 18, and 24 months after burn injury
Secondary Change in Molecular biomarkers of oxidative and nitrosative stress (isoprostanes, asymmetric dimethylarginine) Urine analysis Discharge (usually 30 days post burn) and 6, 12, 18, and 24 months after burn injury
Secondary Changes in quality of life Questionnaires Discharge (usually 30 days post burn) and 6, 12, 18, and 24 months after burn injury
See also
  Status Clinical Trial Phase
Completed NCT05023135 - DeepView SnapShot Portable (DV-SSP): Device Training Study
Completed NCT05276869 - Reliability and Feasibility of WeeFIM Instrument to Measure Functional Independence in Pediatric Burns
Completed NCT04548635 - VR for Burn Dressing Changes at Home Phase 2/Phase 3
Not yet recruiting NCT06076031 - Effects of Applying Streaming Media on Reducing Pain in Patient With Second-degree Burn During Changing Dressing N/A
Recruiting NCT05084248 - Vitamin D Deficiency in Adults Following a Major Burn Injury Phase 4
Completed NCT03113253 - TRANexamic Acid to Reduce Bleeding in BURN Surgery Phase 4
Recruiting NCT04090424 - Assessment of Safety and Effectiveness of NovoSorb® BTM in Severe Burns N/A
Not yet recruiting NCT05649891 - Checklists Resuscitation Emergency Department N/A
Withdrawn NCT03159182 - Study of Silicone Material Inserts To Treat Burn Scars N/A
Recruiting NCT02904941 - Human Amniotic Versus Synthetic Membrane as a Transient Skin Cover for Pediatric Burns N/A
Completed NCT02681757 - Comparison of Mepitel Ag vs Antibiotic Ointment Used With Soft Cast Technique for Treatment of Pediatric Burns N/A
Recruiting NCT01812941 - Evaluation of Mitochondrial Dysfunction in Severe Burn and Trauma Patients N/A
Completed NCT01437852 - StrataGraft® Skin Tissue as an Alternative to Autografting Deep Partial-Thickness Burns Phase 1
Completed NCT01214811 - Open Multi-centre Investigation to Evaluate Signs and Symptoms of Local Inflammation/Infection on Chronic Ulcers and Partial Thickness Burns When Using Mepilex Border Ag as an Anti-microbial Wound Dressing Phase 3
Completed NCT01061502 - Efficacy Study of a Bioelectric Dressing to Treat Skin Graft Donor Site Wounds Phase 1/Phase 2
Terminated NCT00822796 - Thermogard™ Efficacy Trial N/A
Terminated NCT00824681 - Effect of Music Therapy on Families of Burn Patients Phase 1
Terminated NCT00634166 - Effects of Therapy With Sulfamylon® 5% Topical Solution Compared to a Historical Control Group Phase 4
Terminated NCT00464386 - Continuous Glucose Monitoring (POC) in the ICU N/A
Withdrawn NCT00216983 - Proline Metabolism in Severely Burned Patients: Effect of Modulated Parenteral Feeding N/A